Renal cancer: the carcinogen roster and prevention

Renal cell carcinoma's full acquired roster lands on one barrier law: tobacco (RR 1.6) and trichloroethylene (RR 1.42, IARC Group 1) each place on the kidney R19 axis at their cited risk. Removal divides combined risk (prevention). Aristolochic acid is a distinct entity — urothelial (UUC), not RCC. Grade [H] prevention on [F]/[V]/[L].

Under the ownership contract, circulatory owns the acquired, carcinogen-driven kidney cancer. Each RCC carcinogen (tobacco, trichloroethylene) is placed on the kidney R19 drive axis by inverting the barrier law at its cited relative risk; removing a driver divides the combined risk. Aristolochic acid is documented honestly as upper-tract urothelial carcinoma plus aristolochic-acid nephropathy — a different cancer, not RCC.

One barrier law, the whole roster

Renal cell carcinoma is the acquired, dynamics-defined kidney cancer the framework owns. Each known carcinogen is a sustained drive on the kidney R19 switch (§7), placed on the drive axis by inverting the barrier law at its cited relative risk.

\text{remove driver }i:\ RR_{comb}\to RR_{comb}/RR_i

Tobacco and trichloroethylene

Tobacco smoke (RR 1.6 ever-smoker) and trichloroethylene (RR 1.42; IARC Group 1, 2012) both round-trip exactly to their cited risks on the kidney axis. Trichloroethylene is notable mechanistically: its renal genotoxic metabolite acts through the same VHL pathway whose germline loss defines hereditary RCC — owned as a monogenic entity by the rare-disease volume (ownership contract), cross-referenced here. The prevention consequence is the de-escalation theorem run forward: removing a driver divides the combined risk by its RR (combined 2.3 → 1.42 on removing tobacco), so the highest-RR driver is the first prevention target.

Cross-volume reference · von Hippel-Lindau disease / hereditary clear-cell renal cell carcinoma. Gene-key VHL (3p25-26 (cytoband 3p25.3)), owned by disease_wp — not re-emerged here (MASTER MAP 6.1). germline VHL loss + somatic second hit -> constitutive HIF-alpha (esp. HIF-2alpha) stabilisation -> clear-cell RCC; ~2-4% of all RCC is VHL-syndrome familial, and somatic VHL inactivation is the initiating event in >90% of sporadic clear-cell RCC Seam to this volume: trichloroethylene -- a circulatory-owned ACQUIRED RCC carcinogen placed on the kidney R19 axis in section 22 -- exerts its renal genotoxicity through the SAME VHL/HIF pathway whose germline loss defines hereditary RCC. The acquired drive axis (22) and the germline gene-key entity (disease_wp) therefore meet at VHL: one is an exogenous sustained drive, the other a heritable predisposing loss of the same gatekeeper. [V] identity + seam (barrier-height derivation owned by disease_wp; gamma^2/4 grounding [O]/[H]) Anchor: VHL maps to 3p25-26; germline VHL -> VHL disease with clear-cell RCC (NCI PDQ, Genetics of VHL Syndrome); pVHL/HIF axis and >90% sporadic somatic inactivation (Kaelin, Clin Cancer Res 2004;10(18):6290s-6295s; 2007;13(2):680s)

Aristolochic acid is urothelial (UUC), not RCC — an honest correction

Aristolochic acid is frequently listed as a kidney carcinogen, but its malignancy is upper-tract urothelial carcinoma (UUC) together with aristolochic-acid nephropathy (a cause of CKD), carrying a specific TP53 A:T→T:A signature. It is IARC Group 1 with a dose-dependent odds ratio reported across the range 1-49 dose-dependent (Hoang meta, PMC3650093). Two honest consequences: it is a different cancer of a different tissue (urothelium, whose master gene is unmeasured), so it is documented but not forced onto the RCC axis; and its potency (OR up to 49) exceeds the smoking-calibrated kidney axis, which saturates near RR 2.2 at the spinodal — on the framework's own logic, a hint that aristolochic acid drives cells past the irreversibility threshold. Prevention is direct: avoid Aristolochia herbal remedies.

Status

The roster placement is forced [F] and round-trips [V] to IARC/meta anchors [L]; absolute incidence is [O]. The framework's contribution is prevention and stratification — the established curative and systemic care of RCC (nephrectomy, ablation, tyrosine-kinase inhibitors, immunotherapy) is standard of care, not derived here.